2024
Systemic anti-cancer treatment and healthcare utilization at end of life: A SEER Medicare analysis.
Adelson K, Canavan M, Niu J, Zhao H, Nortje N, Xiang J, Giordano S, Cheng L. Systemic anti-cancer treatment and healthcare utilization at end of life: A SEER Medicare analysis. Journal Of Clinical Oncology 2024, 20: 276-276. DOI: 10.1200/op.2024.20.10_suppl.276.Peer-Reviewed Original ResearchEnd-of-lifeSystemic anticancer therapyDay of deathIntensive care unit useIntensive care unitHealthcare utilizationEmergency departmentCombined chemo-immunotherapyEnd-of-life chemotherapy useAssociated with healthcare utilizationImmunotherapy useChemo-immunotherapyIncreased healthcare useEnd of lifeAdverse quality of lifeAssociated with higher EDCare unitQuality of lifeSystemic anti-cancer treatmentHospice useDay hospiceHospice enrollmentSEER-Medicare databaseUse of chemotherapyHealthcare usePrognostic Understanding, Goals of Care, and Quality of Life in Hospitalized Patients with Leukemia or Multiple Myeloma
Shimer S, Allen O, Yang C, Canavan M, Westvold S, Kim N, Morillo J, Parker T, Wallace N, Smith C, Adelson K. Prognostic Understanding, Goals of Care, and Quality of Life in Hospitalized Patients with Leukemia or Multiple Myeloma. Journal Of Palliative Medicine 2024, 27: 879-887. PMID: 38990245, DOI: 10.1089/jpm.2023.0530.Peer-Reviewed Original ResearchGoals of carePrognostic awarenessQuality of lifeIllness understandingPrognostic understandingMultiple myelomaHematologic malignanciesAcute leukemiaFaith-based responseInformed treatment choicesChi-square testCohort of patientsLikelihood ratio chi-square testMount Sinai HospitalTreatment goalsMM cohortSinai HospitalCarePatient populationTreatment choiceHospitalized patientsHematologistsAssess discordanceLeukemiaPatients
2017
Does coaching goals of care discussion skills make a difference?
Bickell N, Adelson K, Gonsky J, Pintova S, Levy B, Lin J, Franco R, Egorova N, Smith C. Does coaching goals of care discussion skills make a difference? Journal Of Clinical Oncology 2017, 35: 6586-6586. DOI: 10.1200/jco.2017.35.15_suppl.6586.Peer-Reviewed Original ResearchAdvanced cancer patientsGOC discussionsCancer patientsCancer prognosisClarity of valuesPoor health literacyQuality of lifeElicit patient valuesEligible patientsIntervention patientsYear prognosisMean ageCare discussionsIntervention groupPatient reportsPatient understandingTreatment goalsHealth literacyDisease processPatientsSide effectsPatient valuesOncologists' communication skillsCommunication skills trainingPrognosisAn EPIC electronic decision support tool to identify percentage of patients with stage IV thoracic or gastrointestinal malignancy who would benefit from concurrent palliative care but do not currently receive it.
Adelson K, Trant A, Framski K, Swidler M, Kashyap N. An EPIC electronic decision support tool to identify percentage of patients with stage IV thoracic or gastrointestinal malignancy who would benefit from concurrent palliative care but do not currently receive it. Journal Of Clinical Oncology 2017, 35: 133-133. DOI: 10.1200/jco.2017.35.8_suppl.133.Peer-Reviewed Original ResearchEpic electronic health recordConcurrent palliative carePalliative careOncologic careElectronic decision support toolPalliative care visitsPC referral rateSmilow Cancer HospitalStandard oncologic careYale-New HavenPalliative care consultStage IV diseasePercentage of patientsPalliative care servicesHealth care utilizationICD-10 diagnosisQuality of lifeVolume of patientsElectronic health recordsAlign careCare consultEligible patientsPC referralEnd of lifeIOM guidelines
2015
Chemotherapy Use, Performance Status, and Quality of Life at the End of Life
Prigerson HG, Bao Y, Shah MA, Paulk ME, LeBlanc TW, Schneider BJ, Garrido MM, Reid MC, Berlin DA, Adelson KB, Neugut AI, Maciejewski PK. Chemotherapy Use, Performance Status, and Quality of Life at the End of Life. JAMA Oncology 2015, 1: 778-784. PMID: 26203912, PMCID: PMC4828728, DOI: 10.1001/jamaoncol.2015.2378.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsChi-Square DistributionFemaleHealth StatusHealth Status IndicatorsHumansLogistic ModelsLongitudinal StudiesMaleMiddle AgedMultivariate AnalysisNeoplasm MetastasisNeoplasm StagingNeoplasmsOdds RatioPalliative CarePatient SelectionProportional Hazards ModelsProspective StudiesQuality of LifeRisk AssessmentRisk FactorsStress, PsychologicalSurveys and QuestionnairesTerminal CareTime FactorsTreatment OutcomeUnited StatesConceptsEnd-stage cancerGood performance statusBaseline performance statusQuality of lifeChemotherapy usePatient performance statusPerformance statusPalliative chemotherapyEastern Cooperative Oncology Group performance statusGood baseline performance statusPoor baseline performance statusProgressive metastatic cancerProgressive metastatic diseasePoor performance statusSolid tumor patientsClinical Oncology guidelinesLongitudinal cohort studyOutpatient oncology clinicsChemotherapy regimenEnd of lifeCohort studyMetastatic diseaseOncology clinicPatient survivalOncology guidelines
2005
Treatment of hot flushes in breast and prostate cancer
Adelson KB, Loprinzi CL, Hershman DL. Treatment of hot flushes in breast and prostate cancer. Expert Opinion On Pharmacotherapy 2005, 6: 1095-1106. PMID: 15957964, DOI: 10.1517/14656566.6.7.1095.Peer-Reviewed Original ResearchMeSH KeywordsAminesAntineoplastic Agents, HormonalBreast NeoplasmsCimicifugaContraindicationsCyclohexanecarboxylic AcidsDrug Therapy, CombinationElectroacupunctureExcitatory Amino Acid AntagonistsFemaleGabapentinGamma-Aminobutyric AcidHormone Replacement TherapyHot FlashesHumansMaleNeoplasms, Hormone-DependentOrchiectomyParoxetinePhytotherapyPlant PreparationsProstatic NeoplasmsRandomized Controlled Trials as TopicSelective Serotonin Reuptake InhibitorsConceptsHormone replacement therapyHot flushesBreast cancerReplacement therapyProstate cancerSelective serotonin reuptake inhibitorsChemotherapy-induced menopauseMenopausal age womenMainstay of treatmentThrombo-embolic eventsSerotonin reuptake inhibitorsHealthy menopausal womenCommon health problemHot flush symptomsQuality of lifeMedical castrationHormonal therapyOvarian suppressionAndrogen ablationPerimenopausal periodNonhormonal agentsReuptake inhibitorsSignificant morbidityCancer survivorsMenopausal women